Project Grant R01CA216424

This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research to investigate how inhibition of the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) to metabolic disruptions, leading to cell death. The $165,196 award to Duke University was made on December 1, 2024 and is scheduled for completion by May 31, 2026. The researchers have performed a CRISPR/Cas9 screen to identify combination therapy targets that synergize with the ABL...

This $524,400 Project Grant award from the National Cancer Institute's (CFDA 93.393 - Cancer Cause and Prevention Research) program will fund research at the University of Texas MD Anderson Cancer Center to investigate mechanisms by which reactive aldehydes promote genome instability and disease. The key objectives are to: 1) Determine how aldehydes impair the function of the HSP90 protein folding chaperone, and 2) Delineate the proteotoxic and genotoxic effects of aldehydes on genome...

This Project Grant award of $730,407, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research investigating how inhibition of the ULK1 protein kinase, which controls autophagy, can rewire the metabolism of lung tumor cells and tumor-infiltrating T cells. The key products and services to be delivered under this 5-year award include: Establishing the role of ULK1 inhibition in altering lung tumor cell metabolism in vivo using...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,966 in funding to Cloverleaf Bio, Inc. to advance the pre-clinical development of a novel therapeutic approach for treating hepatocellular carcinoma (HCC), the most common form of liver cancer. The key objectives are to: (1) develop additional in vitro-optimized therapeutic transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) to target multiple...

This federal Project Grant award for $237,724, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research by New York University School of Medicine to develop novel antibody-based therapeutics targeting the plasma membrane vacuolar ATPase (pmvATPase) as an anti-cancer therapy. The long-term goal is to validate pmvATPase as a therapeutic target and create selective antibodies that inhibit its activity, which is associated with...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is supporting research to develop a promising low-toxicity therapeutic strategy for cervical cancer. The $376,490 award to the University of Oklahoma Health Sciences Center will investigate combining a C-MYC inhibitor (MYCI975) with the novel investigational agent SHETA2 to target metabolic reprogramming in cervical cancer. Preliminary studies indicate SHETA2 disrupts mitochondrial function and...

The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...